Nowell Solish1, Jason K Rivers, Shannon Humphrey, Channy Muhn, Chris Somogyi, Xiaofang Lei, Meetu Bhogal, Carrie Caulkins. 1. *Department of Dermatology, University of Toronto, Toronto, Ontario, Canada; †Department of Dermatology and Skin Science, University of British Columbia, Vancouver, British Columbia, Canada, and Pacific Dermaesthetics, Vancouver, British Columbia, Canada; ‡Dermetics, Burlington, Ontario, Canada, and Department of Dermatology, McMaster University, Hamilton, Ontario, Canada; §Allergan plc, Irvine, California; ‖Allergan plc, Markham, Ontario, Canada.
Abstract
BACKGROUND: Various onabotulinumtoxinA doses are effective in treating forehead lines (FHL), with a trend toward lower doses. OBJECTIVE: To evaluate efficacy and safety of onabotulinumtoxinA dose-ranging treatment of FHL when the frontalis area and glabellar complex are treated together. MATERIALS AND METHODS:Adults with moderate-to-severe FHL receivedonabotulinumtoxinA 40 U (FHL, 20 U; glabellar lines [GL], 20 U), 30 U (FHL, 10 U; GL, 20 U), or placebo. Response was assessed at weeks 1, 2, day 30, and monthly to day 180. Coprimary efficacy end points were investigator- and subject-assessed Facial Wrinkle Scale scores of none or mild (day 30). Patient-reported outcomes, onset/duration of effect, and adverse events (AEs) were evaluated. RESULTS:Responder rates (investigator/subject, respectively) were 40-U group, 91.2%/89.5%; 30-U group, 86.4%/81.4%; placebo, 1.7%/5.1%. OnabotulinumtoxinA resulted in significantly greater responder rates than placebo (p < .001). Adverse events were mild to moderate and similar between groups (most common AEs: nasopharyngitis [4.6%] and headache [4.0%]). CONCLUSION: Treatment of FHL with onabotulinumtoxinA 40 and 30 U (in frontalis and glabellar complex muscles) was tolerable, effective, and sustained. Both doses significantly reduced FHL severity; however, the 40-U dose demonstrated a trend toward greater sustained benefit and longer duration of effect versus the 30-U dose, with similar AE rates.
RCT Entities:
BACKGROUND: Various onabotulinumtoxinA doses are effective in treating forehead lines (FHL), with a trend toward lower doses. OBJECTIVE: To evaluate efficacy and safety of onabotulinumtoxinA dose-ranging treatment of FHL when the frontalis area and glabellar complex are treated together. MATERIALS AND METHODS: Adults with moderate-to-severe FHL received onabotulinumtoxinA 40 U (FHL, 20 U; glabellar lines [GL], 20 U), 30 U (FHL, 10 U; GL, 20 U), or placebo. Response was assessed at weeks 1, 2, day 30, and monthly to day 180. Coprimary efficacy end points were investigator- and subject-assessed Facial Wrinkle Scale scores of none or mild (day 30). Patient-reported outcomes, onset/duration of effect, and adverse events (AEs) were evaluated. RESULTS: Responder rates (investigator/subject, respectively) were 40-U group, 91.2%/89.5%; 30-U group, 86.4%/81.4%; placebo, 1.7%/5.1%. OnabotulinumtoxinA resulted in significantly greater responder rates than placebo (p < .001). Adverse events were mild to moderate and similar between groups (most common AEs: nasopharyngitis [4.6%] and headache [4.0%]). CONCLUSION: Treatment of FHL with onabotulinumtoxinA 40 and 30 U (in frontalis and glabellar complex muscles) was tolerable, effective, and sustained. Both doses significantly reduced FHL severity; however, the 40-U dose demonstrated a trend toward greater sustained benefit and longer duration of effect versus the 30-U dose, with similar AE rates.
Authors: John H Joseph; Corey Maas; Melanie D Palm; Edward Lain; Dee Anna Glaser; Suzanne Bruce; Steven Yoelin; Sue Ellen Cox; Steven Fagien; Sara Sangha; John Maltman; Xiaofang Lei; Mitchell F Brin Journal: Aesthet Surg J Date: 2022-10-13 Impact factor: 4.485
Authors: Cristina Pires Camargo; Jun Xia; Caroline S Costa; Rolf Gemperli; Maria Dc Tatini; Max K Bulsara; Rachel Riera Journal: Cochrane Database Syst Rev Date: 2021-07-05
Authors: Koenraad De Boulle; Alastair Carruthers; Nowell Solish; Jean Carruthers; Wolfgang G Phillipp-Dormston; Steven Fagien; Sara Sangha; Michael Silberberg; Cheri Mao Journal: Plast Reconstr Surg Glob Open Date: 2020-03-20
Authors: Vivekanand Kattimani; Rahul Vinay Chandra Tiwari; Khalid Gufran; Bharti Wasan; P H Shilpa; Anas Abdul Khader Journal: J Int Soc Prev Community Dent Date: 2019-04-12